Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy

Bibliography

• WAXMAN DJ, CHEN L, HECHT JE, JOUNAIDI Y: Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab. Rev. (1999) 31(2):503-522.
   PubMed Web of Science ®Google Scholar
• OYAMA T, KAGAWA N, KUNUGITA N et al.: Expression of cytochrome P450 in tumour tissues and its association with cancer development. Front. Biosci. (2004) 9:1967-1976.
   PubMed Web of Science ®Google Scholar
• MURRAY GI, TAYLOR MC, MCFADYEN MC et al.: Tumour-specific expression of cytochrome P450 CYP1B1. Cancer Res. (1997) 57(14):3026-3031.
   PubMed Web of Science ®Google Scholar
• MUSKHELISHVILI L, THOMPSON PA, KUSEWITT DF, WANG C, KADLUBAR FF: In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J. Histochem. Cytochem. (2001) 49(2):229-236.
   PubMed Web of Science ®Google Scholar
• MCFADYEN MC, MURRAY GI: Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol. (2005) 1(2):259-263.
   PubMedGoogle Scholar
• KARLGREN M, MIURA S, INGELMAN-SUNDBERG M: Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. (2005) 207(2 Suppl.):57-61.
   PubMedGoogle Scholar
• KARLGREN M, GOMEZ A, STARK K et al.: Tumour-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. (2006) 341(2):451-458.
   PubMed Web of Science ®Google Scholar
• INGELMAN-SUNDBERG M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. (2005) 5(1):6-13.
   PubMed Web of Science ®Google Scholar
• SAARIKOSKI ST, RIVERA SP, HANKINSON O, HUSGAFVEL-PURSIAINEN K: CYP2S1: A short review. Toxicol. Appl. Pharmacol. (2005) 207(2 Suppl.):62-69.
   PubMedGoogle Scholar
• NELSON DR, ZELDIN DC, HOFFMAN SM et al.: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics (2004) 14(1):1-18.
   PubMedGoogle Scholar
• CHENG JB, LEVINE MA, BELL NH, MANGELSDORF DJ, RUSSELL DW: Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. USA (2004) 101(20):7711-7715.
   PubMed Web of Science ®Google Scholar
• CHOUDHARY D, JANSSON I, STOILOV I, SARFARAZI M, SCHENKMAN JB: Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch. Biochem. Biophys. (2005) 436(1):50-61.
   PubMed Web of Science ®Google Scholar
• AUNG PP, OUE N, MITANI Y et al.: Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloprotease-10 are novel prognostic factors in patients with gastric cancer. Oncogene (2006) 25(17):2546-2557.
   PubMed Web of Science ®Google Scholar
• GIRAULT I, ROUGIER N, CHESNE C et al.: Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. (2005) 33(12):1803-1810.
   PubMed Web of Science ®Google Scholar
• DU L, HOFFMAN SM, KEENEY DS: Epidermal CYP2 family cytochromes P450. Toxicol. Appl. Pharmacol. (2004) 195(3):278-287.
   PubMed Web of Science ®Google Scholar
• DU L, NEIS MM, LADD PA et al.: Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. Toxicol. Appl. Pharmacol. (2006) 213(2):135-144.
   PubMed Web of Science ®Google Scholar
• DU L, NEIS MM, LADD PA, KEENEY DS: Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classical aryl hydrocarbon receptor ligands. J. Pharmacol. Exp. Ther. (2006) (In Press).
   Google Scholar
• THOMAS RD, GREEN MR, WILSON C et al.: Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells. Chem. Biol. Interact. (2006) 160(3):204-216.
   PubMed Web of Science ®Google Scholar
• YAMASHITA R, SUZUKI Y, SUGANO S, NAKAI K: Genome-wide analysis reveals strong correlation between CpG islands with nearby transcription start sites of genes and their tissue specificity. Gene (2005) 350(2):129-136.
   PubMedGoogle Scholar
• SANTOS KF, MAZZOLA TN, CARVALHO HF: The prima donna of epigenetics: the regulation of gene expression by DNA methylation. Braz. J. Med. Biol. Res. (2005) 38(10):1531-1541.
   PubMed Web of Science ®Google Scholar
• GOMEZ A, RODRIGUEZ-ANTONA C, MKRTCHIAN S, KARLGREN M, INGELMAN-SUNDBERG M: DNA methylation governs the expression of CYP2W1. Drug Metab. Rev. (2005) 37(S1):40.
   Google Scholar
• KARLGREN M, STARK K, OLIW E, INGELMAN-SUNDBERG M: A novel human cytochrome P450 enzyme, CYP2W1. Analysis of function and distribution. Drug Metab. Rev. (2005) 37(S1):51.
   Web of Science ®Google Scholar
• WU Z, SOHL C, SHIMADA T, GUENGERICH F: Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol. Pharmacol. (2006) 69(6):2007-2014.
   PubMed Web of Science ®Google Scholar
• YOSHIOKA H, KASAI N, IKUSHIRO S et al.: Enzymatic properties of human CYP2W1 expressed in Escherichia coli. Biochem. Biophys. Res. Commun. (2006) 345(1):169-174.
   PubMed Web of Science ®Google Scholar
• RIEGER MA, EBNER R, BELL DR et al.: Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. (2004) 64(7):2357-2364.
   PubMed Web of Science ®Google Scholar
• JIANG JG, CHEN CL, CARD JW et al.: Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is upregulated in human tumours. Cancer Res. (2005) 65(11):4707-4715.
   PubMed Web of Science ®Google Scholar
• GIBSON P, GILL JH, KHAN PA et al.: Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol. Cancer Ther. (2003) 2(6):527-534.
   PubMed Web of Science ®Google Scholar
• STOILOV I, AKARSU AN, SARFARAZI M: Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. (1997) 6(4):641-647.
   PubMed Web of Science ®Google Scholar
• STOILOV I, AKARSU AN, ALOZIE I et al.: Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. (1998) 62(3):573-584.
   PubMed Web of Science ®Google Scholar
• GRIBBEN JG, RYAN DP, BOYAJIAN R et al.: Unexpected association between induction of immunity to the universal tumour antigen CYP1B1 and response to next therapy. Clin. Cancer Res. (2005) 11(12):4430-4436.
   PubMed Web of Science ®Google Scholar